Cardiovascular risk factors for cognitive deficiency and options for correction

N. N. Koberskaya
DOI: https://doi.org/10.21518/2079-701x-2022-16-2-35-43
2022-03-10
Meditsinskiy sovet = Medical Council
Abstract:Cardiovascular risk factors for the development of cognitive impairment and Alzheimer’s disease are ranked among the most significant ones, especially in elderly patients. The review provides data on the influence of such factors as arterial hypertension, arterial hypotension, heart failure, coronary heart disease, etc. on the development of cognitive deficiency. The presence of two or more of these risk factors generally tends to increase the possibility of the development of Alzheimer’s disease. The author examines the relationship between these factors and the development of Alzheimer’s disease. Insights into how CVD risk factors can cause progressive cognitive impairment provides further insight into the pathophysiology of Alzheimer’s disease and the identification of methods to prevent or treat CV risk factors for cognitive decline. The course and outcome of cardiovascular diseases depend on the patient’s age, previous medical history, lifestyle, primary prevention, genetic and pathological factors that affect structural and hemodynamic functions. The article addresses issues of therapy of these disorders. Methods of non-pharmacological therapy are discussed: the importance of the patient’s lifestyle, physical activity, nutritional issues, social activity of patients. Much attention is paid to the role of cognitive training in the management of patients with cognitive impairments. The correction of risk factors for stroke and the progression of chronic circulatory disorders is one of the most elaborated areas. The therapeutic potential drugs with a multifactorial mechanism of action are discussed. One of them is Ginkgo biloba extract EGb 761®, which meets the regulated content of active ingredients (flavone glycosides, terpene lactones and ginkgolic acid) and, perhaps, promises to be a more rational choice in the treatment of cognitive impairment. The role of Ginkgo biloba extract EGb 761® in the treatment of cardiovascular diseases is discussed.
What problem does this paper attempt to address?